New video series explores the impact of ADHD on relationships and the role of Qelbree in helping Jay’s ADHD symptom managementROCKVILLE, Md., May 29, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals is expanding its partnership with TV personality and sports reporter Jay Glazer in a new content series featuring his wife, Rosie Glazer. The series, which launches its first episode on the All About ADHD YouTube channel in May for Mental Health Awareness Month, offers an intimate look at how ADHD impacts relat ...

ROCKVILLE, Md., May 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company received Paragraph IV Notice Letters from third parties notifying Supernus that the third parties submitted Abbreviated New Drug Applications (ANDAs) for viloxazine extended-release capsules, eq. 100, 150, and 200 mg base. Supernus is currently ...

ROCKVILLE, Md., May 20, 2025 (GLOBE NEWSWIRE) -- Actress, author, podcaster, and mom, Busy Philipps, is stepping into an important new role as 'Ms. Represented' in partnership with Supernus Pharmaceuticals for a new campaign aimed at empowering women with attention-deficit/hyperactivity disorder (ADHD) to understand their symptoms. The campaign, which launched during Mental Health Awareness Month (May) on Bustle – a leading online destination for women's news – draws on Busy's personal journey navigating he ...

Core Insights - Supernus Pharmaceuticals reported $149.82 million in revenue for Q1 2025, a year-over-year increase of 4.3% and a surprise of +2.91% over the Zacks Consensus Estimate of $145.59 million [1] - The company achieved an EPS of $0.42, compared to $0.00 a year ago, with an EPS surprise of +10.53% against the consensus estimate of $0.38 [1] Revenue Breakdown - Trokendi XR generated $12.80 million in net product sales, exceeding the average estimate of $8.58 million, but representing a year-over-year decline of -20% [4] - Oxtellar XR reported $10.20 million in net product sales, below the average estimate of $12.29 million, with a significant year-over-year decrease of -62.1% [4] - Qelbree achieved $64.70 million in net product sales, slightly below the average estimate of $65.54 million, but showing a year-over-year increase of +43.5% [4] - Total net product sales amounted to $141.99 million, surpassing the average estimate of $140.61 million, reflecting a year-over-year growth of +2.6% [4] - Royalty revenues reached $7.84 million, exceeding the estimated $5.80 million, with a year-over-year increase of +51.2% [4] - GOCOVRI net product sales were $30.70 million, above the average estimate of $30.13 million, marking a year-over-year increase of +15.9% [4] - Other net product sales totaled $8.60 million, surpassing the average estimate of $7.38 million, with a year-over-year growth of +19.4% [4] - APOKYN reported $15 million in net product sales, below the average estimate of $16.70 million, reflecting a year-over-year decline of -10.2% [4] Stock Performance - Supernus shares returned +0.4% over the past month, while the Zacks S&P 500 composite increased by +11.5% [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance against the broader market in the near term [3]

First quarter 2025 net sales of Qelbree® increased 44% to $64.7 million, compared to the same period in 2024.First quarter 2025 net sales of GOCOVRI® increased 16% to $30.7 million, compared to the same period in 2024.First quarter 2025 total revenues increased 4% to $149.8 million, compared to the same period in 2024. First quarter 2025 total revenues excluding Trokendi XR® and Oxtellar XR® net sales (non-GAAP)(1) increased 26% compared to the first quarter of 2024.First quarter 2025 operating loss of $(10 ...

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q4 2024 Earnings Conference Call February 25, 2025 4:30 PM ET Company Participants Peter Vozzo – Investor Relations-ICR Healthcare Jack Khattar – Chief Executive Officer Tim Dec – Chief Financial Officer Conference Call Participants Andrew Tsai – Jefferies Stacy Ku – TD Cowen Annabel Samimy - Stifel David Amsellem – Piper Sandler Kristen Kluska - Cantor Fitzgerald Operator Good afternoon, and welcome to Supernus Pharmaceuticals Fourth Quarter and Full Year 2024 F ...